Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Profit / Loss per share

Profit / Loss per share

6 Months Ended

Jun. 30, 2023

Note 4 — Loss per share

The following tables reconcile the numerator and denominator in the basic and diluted loss per share computation (in thousands):


	Three months ended				Six months ended
	June 30,				June 30,
	2023		2022		2023		2022
Numerator for basic and diluted loss per share
Net loss attributable to ordinary shareholders	$	(21,389)	$	(44,520)	$	(20,353)	$	(94,785)
Net loss attributable to ordinary shareholders used for basic and diluted loss per share	$	(21,389)	$	(44,520)	$	(20,353)	$	(94,785)


	Three months ended		Six months ended
	June 30,		June 30,
	2023	2022	2023	2022
Denominator for basic loss per share - Weighted average shares outstanding	1,108,166,960	962,794,072	1,050,071,434	951,474,546

The dilutive effect of 201,688,491 and 150,711,054 stock options outstanding as of June 30, 2023 and 2022 respectively have been excluded from the diluted loss per share calculation for the three and six months ended June 30, 2023 and 2022 because they would have an antidilutive effect on the loss per share for the period. The stock options outstanding as of June 30, 2023 includes a provisional amount of 35,156,344 replacement awards granted to TCR² grantholders on June 1, 2023.